Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Soaanz, Demadex (DSC)
Synonyms :
torsemide
Class :
Diuretics, Loop
Brand Name :
Soaanz, Demadex (DSC)
Synonyms :
torsemide
Class :
Diuretics, Loop
Dosage forms and strengthsÂ
TabletÂ
100mgÂ
60mgÂ
20mgÂ
10mgÂ
5mgÂ
The initial oral dose is 10 to 20 mg once daily, the dosage can be enhanced, by doubling it, till the desirable diuretic outcome is attained
Doses exceeding 200 mg have not undergone thorough investigation
Indicated for hepatic cirrhosis
The initial once daily oral dose is 5 to 10 mg in conjunction with an aldosterone antagonist or a potassium-sparing diuretic
the dosage can be enhanced, by doubling it, till the desirable diuretic outcome is attained
Doses exceeding 40 mg have not undergone thorough investigation
Initial oral dose: Start with a daily dose of 2.5 to 5 mg, the dosage can potentially be raised to 10 mg a day after 4-6 weeks as needed
Additional antihypertensive medication should be considered if the 10-mg dose is not effective
Indicated for hepatic cirrhosis
The initial once daily oral dose is 5 to 10 mg in conjunction with an aldosterone antagonist or a potassium-sparing diuretic
The dosage can be enhanced, by doubling it, till the desirable diuretic outcome is attained
Doses exceeding 40 mg have not undergone thorough investigation
Safety and efficacy are not well established
Refer adult dosing
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may diminish the excretion when combined with lithium
may diminish the excretion when combined with lithium
May enhance the toxic effects of the other by pharmacodynamic synergism
may decrease the absorption when combined with thiazide diuretics
may increase the sensitivity to pressor effects
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
CYP2C9 enhancers may decrease the the bioavailability of torsemide 
opioid agonists increase the toxicity of diuretics
opioid agonists increase the toxicity of diuretics
It may enhance the serum concentration when combined with CYP2C19 Inhibitors
It may enhance the serum concentration when combined with CYP2C19 Inhibitors
It may enhance toxicity when combined with beclomethasone, inhaled by enhancing elimination
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
acetaminophen/dextromethorphan/pseudoephedrine/guaifenesin
it may enhance the risk of nephrotoxicity when combined with Diuretics
brompheniramine, dextromethorphan and phenylephrine
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may increase the adverse/toxic effect of diuretics
may increase the adverse/toxic effect of diuretics
may increase the adverse/toxic effect of diuretics
may increase the adverse/toxic effect of diuretics
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may have an increased hypercalcemic effect when combined with vitamin D analogs
both the drugs may enhance the risk of nephrotoxicity
The interaction may enhance the hypotensive effects of pholcodine
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
The interaction may enhance the hypotensive effects of opioid anti-tussive agents
it may reduce the effect of antihypertensive agents
Diacerein may increase the therapeutic effect of Diuretics
Amphetamines may reduce the antihypertensive effect of antihypertensive Agents.
Amphetamines may reduce the antihypertensive effect of antihypertensive Agents.
Amphetamines may reduce the antihypertensive effect of antihypertensive Agents.
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
may increase the toxic effects of diuretics
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may increase the toxic effects
may increase the toxic effects of opioid agonists
may increase the adverse/toxic effect of Opioid Agonists
buprenorphine,long-acting injectionÂ
may increase the adverse/toxic effect of Opioid Agonists
polyethylene glycol and electrolytesÂ
They may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
diacerein: they may increase the therapeutic effect when combined with diuretics
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
acetaminophen/dextromethorphan/pseudoephedrine/guaifenesin
It may enhance the risk of bleeding when combined with Decongestants
brompheniramine, dextromethorphan and phenylephrine
It may enhance the risk of bleeding when combined with Decongestants
It may enhance the risk of bleeding when combined with Decongestants
it increases the effect of hypokalemia of thiazide and other diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
mu-opioid receptor agonists: they may increase the toxic effect of diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may diminish the excretion of thiazide diuretics
may diminish the excretion of thiazide diuretics
may diminish the excretion of thiazide diuretics
may diminish the excretion of thiazide diuretics
may diminish the excretion of thiazide diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may have an increased orthostatic hypotensive effect when combined with thiazide diuretics
glycopyrrolate inhaled and formoterolÂ
may enhance the effects of the other by pharmacodynamic synergism
Actions and SpectrumÂ
It promotes the excretion of water, salt, and chloride by blocking the kidneys’ ability to reabsorb these ions. Reduced fluid volume and greater urine output result from this. It also demonstrates the vasodilatory qualities, which dilate blood vessels and reduce blood pressure by lowering peripheral vascular resistance.Â
Frequency defined
1-10%
Nervousness (1%)
Insomnia (1%)
Nausea (2%)
Dyspepsia (2%)
Diarrhea (2%)
Cough (2%)
Constipation (2%)
Rhinitis (3%)
Dizziness (3%)
Electrolyte imbalance (2-4%)
Headache (7%)
Excessive urination (7%)
Black Box Warning:
None
Contraindication/Caution:Â
HypersensitivityÂ
Hepatic ComaÂ
Imbalance in the electrolytesÂ
Liver CirrhosisÂ
Pregnancy warnings:Â Â Â
Pregnancy category: US FDA pregnancy category: B
Lactation:Â Excreted into human milk is unknown
Pregnancy Categories:
Category A:Â Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C:Â there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D:Â adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X:Â Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N:Â There is no data available for the drug under this category
PharmacologyÂ
It promotes the excretion of water, salt, and chloride by blocking the kidneys’ ability to reabsorb these ions. Reduced fluid volume and greater urine output result from this. Â
PharmacodynamicsÂ
It works by blocking a transport protein in the kidneys called the Na+/K+/2Cl- co-transporter. This transporter normally helps reabsorb electrolytes from the urine back into the bloodstream.Â
PharmacokineticsÂ
AbsorptionÂ
Peak plasma concentration: 1 to 2 hours.Â
DistirbutionÂ
Limited data availableÂ
MetabolismÂ
It involves hepatic metabolism through conjugation and oxidationÂ
Elimination/ExcretionÂ
Elimination half life:3 to 4hours.Â
AdministrationÂ
It is administered orally in the form of tabletÂ
Patient information leaflet
Generic Name: torsemide
Why do we use torsemide?
It is used to treat edema and fluid accumulation caused by heart failure, renal illness and liver cirrhosis.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
